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CoRESTa b s t r a c t
A target with therapeutic potential, lysine-speciﬁc demethylase 1A (KDM1A) is a regulator of gene
expression whose tower domain is a protein–protein interaction motif. This domain facilitates
the interaction of KDM1A with coregulators and multiprotein complexes that direct its activity to
nucleosomes. We describe the design and characterization of a chimeric ‘towerless’ KDM1A, termed
nD150 KDM1ADTower KDM1B chimera (chKDM1ADTower), which incorporates a region from the
paralog lysine-speciﬁc demethylase 1B (KDM1B). This chimera copuriﬁes with FAD and displays
demethylase activity, but fails to bind the partner protein corepressor of the RE1-silencing tran-
scription factor (CoREST). We conclude that KDM1A catalysis can be decoupled from
tower-dependent interactions, lending chKDM1ADTower useful for dissecting molecular contribu-
tions to KDM1A function.
 2015 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
In 2004, lysine-speciﬁc demethylase 1A (KDM1A also known as
LSD1/BHC110/AOF2/KIAA0601/p110b) became the ﬁrst histone
demethylase to be isolated and characterized [1] and has subse-
quently been identiﬁed as a potential therapeutic target [2–4].
KDM1A is a ﬂavin-dependent amine oxidase that demethylates
mono- and dimethylated lysine residues at positions 4 and 9 on his-
tone H3 (H3K4me1/2 and H3K9me1/2), leading to gene activation
and repression, respectively [1,5,6]. This 852 amino acid (aa)polypeptide is composed of three structured domains (Fig. 1A).
The catalytic amine oxidase domain (AOD) houses a single,
non-covalently bound ﬂavin adenine dinucleotide (FAD) cofactor
required for catalysis while the N-terminal SWI3p, Rsc8p, and
Moira (SWIRM) domain is commonly found in
chromatin-associating proteins (Fig. 1B) [7–10]. The ‘tower’ domain
is a nearly 100 aa AOD insert that forms an approximately 90 Å long
antiparallel coiled–coil from two a-helices (termed TaA and TaB)
linked by a tight turn (Fig. 1B) [7,8]. Unprecedented among related
amine oxidases [1], the tower domain serves as a protein interaction
motif and facilitates KDM1A incorporation into multiprotein regu-
latory complexes that dictate its cellular function [11].
One of the best-studied tower domain interaction partners is
the corepressor of the RE1-silencing transcription factor
(CoREST/RCOR1/KIAA0071), which facilitates demethylation of
nucleosomal substrates by bridging KDM1A to chromatin through
its DNA-binding SANT domains [8,12–17]. Additionally, CoREST
orchestrates the inclusion of enzymes such as KDM1A and histone
deacetylases as catalytic subunits within modular multiprotein
complexes [18,19]. KDM1A activity is further governed by other
homologous proteins that bind the tower domain and perform
similar functions in different molecular contexts, such as the
Fig. 1. Domain maps and structural overview of KDM1A and KDM1B. (A) Domain maps of KDM1A and KDM1B. SWIRM domains are shown in green, AODs are shown in
magenta, tower domain is shown in blue, C4H2C2 domain is shown in orange, Zf-CW domain is shown in cyan, and linker is shown in purple. Structural overview of (B)
KDM1A (PDB 2IW5) and (C) KDM1B (PDB 4HSU). Coloring scheme follows that of domain map above, FAD cofactor is shown in yellow, and N and C-termini are labeled. Zinc
ions in KDM1B structure are shown as gray spheres.
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22]. Therefore, one of the most signiﬁcant challenges is under-
standing the impact of these tower-dependent interactions on
KDM1A speciﬁcity, catalysis, and positioning within chromatin.
In order to evaluate these tower-dependent interactions inde-
pendent of demethylase activity, a KDM1A tower domain deletion
mutant is highly desired. Indeed, several groups have generated
such mutants, but were limited by a lack of enzymatic activity
[7,8,21,23]. These studies suggest that either the tower domain is
inherently required for KDM1A catalysis or that the methods cho-
sen to bridge the tower region were not conducive to proper active
site folding. Interestingly the recent characterization of the KDM1A
paralog KDM1B provides a unique opportunity to investigate this
dichotomy [24]. KDM1B lacks a tower domain (Fig. 1A) but con-
serves the AOD architecture, sharing a 2.0 Å RMSD compared to
KDM1A, despite a modest sequence similarity (<25%)
(Fig. 1B and C). As this paralog overcomes exclusion of the towerdomain in a manner that preserves a KDM1A-like active site con-
formation, we sought to use it as a template for engineering a chi-
meric KDM1A enzyme.
Here we report the rational design and characterization of a
KDM1A tower domain deletion chimera. KDM1A and KDM1B
sequence and structural alignments suggested that KDM1B resi-
dues V494–L531 could replace the KDM1A tower domain (residues
T389–R524) with minimal active site disturbance. This construct,
termed chKDM1ADTower, copuriﬁed from Escherichia coli cellular
lysates with a stoichiometric equivalent of FAD. As expected,
chKDM1ADTower failed to bind CoREST. However, unlike previous
tower deletion mutants, our chimera exhibits kinetic parameters
nearly identical to those of unaltered KDM1A and KDM1B, suggest-
ing that the tower domain is not required for catalytic activity. The
chKDM1ADTower chimera therefore decouples tower-dependent
protein interactions from catalysis and provides a tool to assess
the effects of KDM1A mistargeting and orphanization.
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2.1. Reagents and materials
Clones of genes encoding Homo sapiens nD150 KDM1A
(UniProtKB accession No. O60341) and full-length KDM1B
(UniProtKB accession No. Q8NB78) were codon optimized for
E. coli by GenScript (Piscataway, NJ) and subcloned into pET-15b
(Novagen) with NdeI and XhoI (New England Biolabs; NEB). The
pDB-HisGST vector was obtained from the DNASU Plasmid
Repository. Buffer salts were obtained from Sigma, EMD
Millipore, and JT Baker. Tween 20 was obtained from AMRESCO.
Protein puriﬁcation was conducted using an ÄKTA FPLC
(Amersham Biosciences).
2.2. Alignment of KDM1A and KDM1B and generation of a chimera
model
Primary amino acid sequences of KDM1A and KDM1B were
aligned using Clustal Omega [25]. A sequence alignment ﬁgure
(Fig. 2A) was generated utilizing ESPript 3.0 [26]. Structural align-
ment of PDB ﬁles 2IW5 and 4HSU (KDM1A [13] and KDM1B [27],
respectively) was conducted with PyMOL [28] (Fig. 2B). To gener-
ate a composite model of the chimera, the headers of PDB ﬁles
2IW5 and 4HSU were deleted and coordinates superimposed using
Coot [29]. KDM1A tower domain residues T389–R524 were
replaced with KDM1B residues V494–L531. The resultant chain
was renumbered and coordinates of the chimera composite model
exported into PyMOL (Fig. 2C). All-atom contacts were validated
with MolProbity [30].
2.3. Cloning of chKDM1ADTower
Joining KDM1A fragments L151–A388 and D525–M852 to
KDM1B residues V494–L531 formed the chimera sequence. A pre-
viously described pET-15b vector containing 6His nD150 KDM1A
(residues 151–852) [31] was used as a template for construction of
the chimera. This entire vector was ampliﬁed with exclusion of the
KDM1A tower domain (residues T389–R524) using primers that
incorporated SalI and KpnI restriction sites and PFU Turbo DNA
polymerase (Agilent) under the following conditions: an initial
denaturation step for 2 min at 95 C, 30 cycles of denaturation
for 30 s at 95 C, annealing for 30 s over a gradient from 54 to
65 C, elongation for 8 min at 72 C, and a ﬁnal elongation step
for 10 min at 72 C. The KDM1B insert (residues V494–L531) was
ampliﬁed with complementary restriction sites under similar con-
ditions, but with an elongation of 1 min at 72 C. The resulting
insert and vector were digested and ligated utilizing a Quick
Ligation Kit (NEB). Restriction sites were removed using a Q5
Site-Directed Mutagenesis Kit (NEB) under the following condi-
tions: an initial denaturation step for 1 min at 98 C, 30 cycles of
denaturation for 30 s at 98 C, annealing for 30 s over a gradient
from 59 to 70 C, elongation for 4 min at 72 C, and a ﬁnal elonga-
tion step for 2 min at 72 C. For primers, see Table S1.
2.4. Expression and puriﬁcation of KDM1A and chKDM1ADTower
Expression and puriﬁcation of wild type nD150 KDM1A was
conducted as previously described [15,31]. The 6His-tagged
nD150 KDM1ADTower KDM1B chimera in pET-15b (i.e.
chKDM1ADTower) was expressed in BL21 Star (DE3) E. coli
(Invitrogen) at 15 C. chKDM1ADTower was puriﬁed under similar
conditions to wild type nD150 KDM1A with minor modiﬁcations.
Approximately 4.5 mg of chKDM1ADTower per liter of culture
were obtained at >95% purity. For more details, please see the
Supplementary Material.2.5. Cofactor analysis of chKDM1ADTower
The method of Aliverti et al. was employed to determine the
FAD molar extinction coefﬁcient [32]. chKDM1ADTower in gel ﬁl-
tration buffer at 1.5–2.0 mg/mL was incubated with SDS to a ﬁnal
concentration of 0.3% (w/v) and monitored until the UV trace sta-
bilized. 15 lM FAD disodium salt hydrate (Sigma) in gel ﬁltration
buffer was used as a standard. The chimera was calculated to cop-
urify with FAD in 1.1:1 ratio (FAD:protein) and to have a molar
extinction coefﬁcient of 10350 M1 cm1 at 455 nm using
e450 = 11300 M1 cm1 for free FAD (FADfree). This value was rou-
tinely used to determine protein concentration.
2.6. Expression and puriﬁcation of His-GST-CoREST-C and His-GST
The His-GST-CoREST-C construct was expressed in BL21 (DE3)
E. coli (Novagen) at 19 C. Protein was puriﬁed by immobilized
metal afﬁnity chromatography (IMAC) and ion exchange chro-
matography (IEC). Approximately 2.0 mg protein per liter of cul-
ture were obtained at >75% purity. The His-GST construct was
expressed and puriﬁed in a similar manner. For more details, see
the Supplementary Material.
2.7. Steady-state demethylase assay
A peptide corresponding to the N-terminal 21 amino acids of
histone H3 with a dimethylated K4 residue (H3K4me21–21) was
prepared as previously described [31,33]. A continuous,
ﬂuorescence-based, steady-state kinetic assay was employed as
previously described with slight modiﬁcations [31,33]. An
HRP-coupled (1 U/mL of HRP) assay monitored enzymatic peroxide
production in 50 mM Tris–HCl (pH 7.85) with 0.01% (w/v) CHAPS
using Amplex Red (50 lM) as the ﬂuorogenic electron acceptor.
All measurements were performed in a ﬁnal volume of 60 lL at
25 C in 96-well format (Corning 3693). Reactions were initiated
with the addition of enzyme (0.35 lMﬁnal concentration). The pro-
duct, resoruﬁn, was monitored with 535 nm excitation and 597 nm
emission wavelengths. Data were analyzed using GraphPad Prism
6.0 (GraphPad Software, San Diego, CA). All data sets were corrected
for background and zero by subtraction of the no enzyme control
and the initial time point, respectively. Initial velocities within
the 10% product conversion limit were ﬁt to the Henri–Michaelis–
Menten equation with non-linear regression analysis.
2.8. His-GST-CoREST-C pull-down interaction assay
A total of 15 lg of puriﬁed His-GST-CoREST-C (residues 286–
482) or 9 lg His-GST were incubated with 12 lg nD150 KDM1A
or 10 lg chKDM1ADTower at 4 C for 16 h in 100 lL of binding
buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4 (pH 7.4), 10 mM DTT, and 0.05% (v/v) Tween 20) contain-
ing 20 lL of Glutathione Sepharose 4 Fast Flow beads (GE
Healthcare). Flow-through (supernatant) was removed and beads
were washed 3 times with 400 lL of binding buffer, resuspended
in 80 lL of 2 SDS sample buffer, and denatured for 2 min at
100 C. Input, beads (bound), and ﬂow-through were analyzed by
SDS–PAGE (4–20% gradient, Bio-Rad) and visualized with
Coomassie Brilliant Blue.
3. Results
3.1. Design of the chKDM1ADTower chimera from KDM1A and KDM1B
alignments
To rationally design a tower domain deletion mutant of KDM1A,
we looked to its ‘towerless’ paralog KDM1B, which performs
Fig. 2. Sequence and structural alignment of KDM1A and KDM1B from H. sapiens and structural model of chKDM1ADTower. Only residues 171–852 of KDM1A were used for
alignment as per Karytinos et al. (A) Sequence alignment of KDM1A and KDM1B. Numbering is based on the primary amino acid sequence of KDM1B. Residues that are
invariant in the two enzymes are highlighted in red and conservative mutations are indicated by red font. Arrows indicate break and splice points chosen for the chimera. (B)
Structural alignment of KDM1A and KDM1B. KDM1A is shown in green and KDM1B is shown in blue. Inset shows 90 rotation and close up of the aligned structures with
TaA and TaB of the tower domain denoted and the KDM1B loop shown in orange. (C) Structural model of chKDM1ADTower. AOD is shown in magenta, SWIRM domain is
shown in green, and KDM1B loop is shown in orange.
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of biomolecules. We therefore used sequence and structural align-
ments to deﬁne a sequence from KDM1B that could replace the
tower domain of KDM1A and maintain active site geometry. As
predicted, a large gap in the sequence alignment of KDM1A and
KDM1B reﬂects the KDM1A tower domain with areas of consider-
able sequence conservation on either side (Fig. 2A). We should note
that a small internal area of apparent homology is likely an artifact
of shared a-helical secondary structure. Subsequent structural
alignment and analysis indicated that while the region
C-terminal to the tower domain is highly similar between the
two enzymes, the corresponding N-terminal region in KDM1B con-
tains a solvent exposed loop not conserved in KDM1A (Fig. 2B). In
order to maintain the interhelical contacts in this region (e.g.
KDM1B W497 with K512 and I516 with V493), we extended the
tower replacement sequence to include this entire loop and also
supplanted a portion of the KDM1A a-helix that contacts the base
of the tower domain (termed aCox or Sa1) [7,8]. The ﬁnal
chKDM1ADTower design incorporated these KDM1B elements into
KDM1A, with a ﬁnal sequence of KDM1A fragments L151–A388
and D525–M852 linked by KDM1B fragment V494–L531 (Fig. S1).
Next, a preliminary evaluation of this design was performed by
generating a composite structural model of chKDM1ADTower
using Coot (Fig. 2C). Subsequent visual inspection of the model in
PyMOL revealed no gross structural abnormalities. Additionally,
analysis of all-atom contacts with MolProbity [30] supported this
observation, as no steric clashes in the replaced tower region were
visible. We therefore predicted that replacement of the KDM1A
tower with the KDM1B loop would result in a properly folded,
active enzyme.3.2. Construction, expression, and puriﬁcation of the chKDM1ADTower
chimera
We next sought to generate the chKDM1ADTower chimera in
which the KDM1B loop was inserted into the KDM1A sequence
in place of the tower domain using restriction digestion cloning.
After insertion, restriction sites were removed to yield a ‘seamless’
chimera that contained only residues from the primary amino acid
sequences of KDM1A and KMD1B (Fig. S2). The chimeric clone was
then overexpressed in E. coli under nearly identical conditions as
reported for wild type KDM1A [15,31] resulting in a visible band
at the expected molecular weight of approximately 70kDa
(Fig. S3A). Puriﬁcation of chKDM1ADTower from E. coli cellular
lysates using a series of chromatographic separations resulted in
a >95% homogenous sample as assessed by SDS–PAGE (Fig. S3B).
Our puriﬁed chKDM1ADTower solution appears yellow in color
(Fig. S3C), suggesting it retains the essential FAD cofactor as previ-
ously observed for KDM1A and KDM1B. Indeed, a UV–visible spec-
trum of the chKDM1ADTower produced characteristic ﬂavin
cofactor absorbance maxima at 380 and 455 nm (Fig. 3) [34]. As
compared to an authentic FAD standard, the molar extinction coef-
ﬁcient (FADbound) of the chKDM1ADTower construct was deter-
mined to be 10350 M1 cm1 at 455 nm [32,34] (Fig. 3).
Furthermore, full cofactor occupancy of chKDM1ADTower was
noted, as a stoichiometric amount of FAD was released upon SDS
treatment. This FAD cofactor was also released into solution as a
function of heat or TCA denaturation (data not shown). These data
therefore suggest that, like KDM1A and KDM1B, the FAD cofactor
of the chimera is non-covalently bound and potentially poised to
initiate catalytic demethylation.
Fig. 3. chKDM1ADTower copuriﬁes with a non-covalently bound FAD cofactor.
chKDM1ADTower was evaluated by UV–Vis and has absorption maxima at 380 and
455 nm (solid green line). The chimera was denatured by treatment with SDS,
releasing the cofactor (dashed blue line). The spectrum of the denatured sample
directly overlays with a FAD standard (solid black line).
Fig. 4. chKDM1ADTower is an active enzyme. (A) Representative linear ﬁt of initial
rates from substrate titration against chKDM1ADTower. Plots are within 10%
product conversion. Concentrations indicated are that of the H3K4me21–21 peptide
substrate. (B) Representative initial velocity curve of the catalytic activity of
chKDM1ADTower. Data are ﬁt to the Henri–Michaelis–Menten equation. Inset is a
reciprocal plot, 1/V0 (s lM1 H2O2) vs. 1/[S] (lM1), to illustrate linear nature of
data.
Table 1
Kinetic Parameters of the Catalytic Activity of chKDM1ADTower with the First 21
Amino Acids of H3 Dimethylated at K4 (H3K4me21–21).
Enzyme Name Kmapp (lM) kcatapp (min1) kcatapp/Kmapp (lM1 min1)
nD150 KDM1A wta,b 2.60 ± 0.2 5.97 ± 0.78 2.28 ± 0.12
nD25 mKDM1B wtc 11.3 ± 1.3 2.00 ± 0.60 0.18 ± 0.04
chKDM1ADTowera 3.21 ± 0.16 0.57 ± 0.01 0.18 ± 0.01
a In 50 mM Tris–HCl (pH 7.85), 0.01% CHAPS (w/v), 50 lM Amplex Red & 1 U/mL
HRP at 25 C in air saturated buffer; peptide titrated from 50 lM to 0 in 2-fold
dilution series (n = 3).
b Values reported by Gaweska et al. [31].
c Values reported by Karytinos et al. [24].
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As the chKDM1ADTower-bound ﬂavin chromophore is sugges-
tive of properly assembled catalytic machinery, we next tested for
bona ﬁde enzymatic activity. Steady-state kinetic parameters of
chKDM1ADTower were evaluated by monitoring enzymatic pro-
duction of H2O2 using a peptide substrate. As shown in Fig. 4,
chKDM1ADTower exhibited well-behaved linear velocities and
demethylated H3K4me21–21 with a Kmapp of 3.21 ± 0.16 lM, a kcatapp
of 0.57 ± 0.01 min1, and a catalytic efﬁciency of
0.18 ± 0.01 lM1 min1. These values compare very favorably to
that of wild type KDM1A and KDM1B enzymes (Table 1). In fact,
the kcatapp/Kmapp of chKDM1ADTower was identical to that of
KDM1B, and only approximately 10-fold lower than that of
KDM1A [24,31]. Interestingly, values of both Kmapp and kcatapp of the
chimera were situated neatly near those of the two enzymes
(Table 1). These data suggest that chKDM1ADTower preserves ele-
ments from both KDM1A and KDM1B as anticipated, and clearly
maintains integrity of the amine oxidase active site. Thus, by graft-
ing the KDM1B loop onto KDM1A, we generated a tower domain
deletion mutant that retains wild type-like demethylase activity.
3.4. chKDM1ADTower does not interact with KDM1A binding partner
CoREST
Having achieved one of our goals in engineering an active
KDM1A tower deletion mutant, we next determined if a known
tower domain interacting protein was precluded from binding the
chimera. The tower domain of wild type KDM1A is a well-known
protein recruitment motif for CoREST [8,12,13]. We therefore
hypothesized that this interaction would be abrogated in the chi-
mera. A GST pull-down assay previously used to evaluate CoREST
binding to wild type KDM1A was employed to assess if
chKDM1ADTower interacts with the C-terminal region of CoREST
(CoREST-C; residues 286–482) [12]. Immobilized
His-GST-CoREST-C or His-GSTwere incubatedwith either wild type
KDM1A or chKDM1ADTower, extensively washed, and the input,
ﬂow-through, and bound proteins visualized by SDS–PAGE. As pre-
viously reported, His-GST-CoREST-C signiﬁcantly bound wild type
KDM1A as compared to the GST control. Conversely, immobilized
His-GST-CoREST-C showed no enrichment for chKDM1ADTowercompared to the control (Fig. 5). These data are in agreement with
previous reports that KDM1A interaction with the C-terminal frag-
ment of CoREST in vitro is mediated mainly through the tower
domain and does not receive signiﬁcant contributions from the
AOD and SWIRM domains [8,13]. Hence our chimera effectively
abrogates association with CoREST, and presumably any other pro-
tein that relies predominantly on the tower domain for binding.
4. Discussion
There is currently a remarkable lack of tools for studying the
inﬂuence of tower-dependent interactions on KDM1A recruitment
into modular multiprotein complexes, substrate speciﬁcity, and
chromatin localization. To address this issue, we here report what
is, to the best of our knowledge, the ﬁrst KDM1A tower deletion
enzyme that retains catalytic activity comparable to wild type
KDM1A and KDM1B. Using sequence and structure-driven design
principles, we have rationally selected boundaries for excision of
theKDM1A towerdomain and replacementwith a bridging segment
from KMD1B. This chimera, termed chKDM1ADTower, copuriﬁes
with a stoichiometric equivalent of FAD and exhibits catalytic
Fig. 5. Unlike wild type KDM1A, chKDM1ADTower is incapable of interacting with
CoREST. Comparable wild type and deletion mutant of KDM1A (chKDM1ADTower)
were incubated with glutathione Sepharose beads in the presence or absence of
His-GST-CoREST-C or His-GST (negative control). The input (top), bound (middle),
and ﬂow-through (bottom) proteins were analyzed by SDS–PAGE. The star (w) in
middle indicates bound KDM1A (lane 7) and the diamonds () in bottom indicate
the unbound KDM1A (lanes 5 and 7) and chKDM1ADTower (lanes 6 and 8) after
incubation with His-GST-CoREST-C or His-GST. The arrows indicate major trunca-
tion products of the His-GST-CoREST-C protein.
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Additionally, our in vitro pull-down studies demonstrate that the
absence of a tower domain in chKDM1ADTower precludes the
tower-dependent binding interaction observed between CoREST
and KDM1A, effectively uncoupling catalysis from
tower-dependent interactions.
Our rational design demonstrates that the tower domain is not
required for catalytic demethylation, thereby overcoming the cat-
alytic inactivity of previously reported KDM1A tower deletion
mutants. We suspect the catalytic deﬁciencies of these mutants
may be attributed to subtle changes in active site geometry that
alter substrate positioning [35]. However, it appears that insertion
of the bridging KDM1B sequence instead mimics the native span
between KDM1A residues A388 and D525 and facilitates folding
of the chimera into a catalytically competent conformation.
Although the catalytic efﬁciency of chKDM1ADTower varies only
minimally from that of KDM1A, we cannot rule out the possibility
that our design may yet be catalytically suboptimal.
By combining catalytic activity with the lack of a tower domain,
our chimera provides a much-needed probe for dissecting the
inﬂuence of tower-dependent protein interactions on KDM1A
function. KDM1A and KDM1B are believed to assemble in a modu-
lar fashion into larger, multivalent complexes that dictate their
intracellular function [11]. As the tower domain is responsible
for a large number of KDM1A interactions, chKDM1ADTower pro-
vides an ideal tool for determining the effects of removing KDM1A
from the control of its interaction partners. We predict this will
likely result in mistargeting of the enzyme on chromatin and alter-
ation of downstream genetic programming. For example, we sus-
pect that chKDM1ADTower will no longer localize with CoRESTin their coregulated promoter regions, thereby functionally
disrupting the transcriptional programs for this subset of genes.
Beyond KDM1A, this strategy of splicing related regions between
functionally related proteins may prove to be an invaluable tool
for investigating domains for which standard domain deletion
proves intractable. This strategy is speciﬁcally useful when
investigating enzymes that exist as subunits of multimeric
complexes.
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